Six insiders buy $114M at $18 each
Watch: Watch upcoming clinical updates or FDA decisions that could validate insider optimism and trigger a re-rating toward analyst targets.
Full analysis
Six distinct insiders, including ECOR1 CAPITAL and MPM BIOVENTURES, purchased AKTS shares at $18 per share totaling $114M. No insider sellers appeared, signaling collective confidence. The stock's 52-week low is $14.72, and average analyst target stands at $32.5, double the current price. AKTS has a strong cash position of $227M against $11.5M debt, but operating margins are deeply negative at -929%.
The concentrated insider buying at a low stock price while maintaining high cash reserves indicates potential catalysts or undervaluation, attracting institutional confidence despite significant losses.
Evidence
Get alerted when AKTS changes direction
We'll email you when our AI detects a shift — reversals, insider clusters, filing red flags.